{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:27:30Z","timestamp":1789698450536,"version":"4.0.1"},"reference-count":38,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peptide Receptor Radionuclide Therapy (PRRT) offers radiomolecular precision medicine for somatostatin receptor (SSTR)-positive advanced neuroendocrine neoplasms (NEN). In cases resistant to Lutetium-177-labeled DOTATATE or DOTATOC PRRT, alpha-therapy with Actinium-225 labeled with SSTR antagonists like DOTA-LM3 can be a notable therapeutic option. This retrospective study aimed to assess [225Ac]Ac-DOTA-LM3 safety in advanced NEN patients (as monotherapy and with Lutetium-177 as TANDEM), survival, and follow-up duration. Thirty-five patients received a total of 57 [225Ac]Ac-DOTA-LM3 cycles (March 2022\u2013September 2024): 24 monotherapies and 33 TANDEM therapies. The pancreas was the most common primary site (n = 19). PRRT-related toxicity was assessed, focusing on hematological, renal, and hepatic toxicity (Common Terminology Criteria for Adverse Events\u2014CTCAE v5.0). Therapy was generally well tolerated, with mostly mild acute adverse events (primarily nausea, n = 8). Some new grade 3\/4 long-term adverse events were reported after treatment: anemia grade 3 (n = 2), leukocytopenia grade 4 (n = 1), absolute neutrophil count reduction grade 3 (n = 1), thrombocytopenia grade 3 (n = 7), acute myeloid leukemia (n = 1), nephrotoxicity grade 3 (n = 2), and hepatotoxicity grade 3 (n = 2). During follow-up, 13 patients died (survival range 5\u201330 months); 22 patients were alive (follow-up range 1\u201318 months). Our retrospective analysis shows that [225Ac]Ac-DOTA-LM3 PRRT is relatively safe concerning acute and long-term toxicity and bears promising survival outcomes in patients progressing after [177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC PRRT.<\/jats:p>","DOI":"10.3390\/cancers17183070","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:53:42Z","timestamp":1758300822000},"page":"3070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225\/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8404-8206","authenticated-orcid":false,"given":"Elisabetta","family":"Perrone","sequence":"first","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"},{"name":"Institute of Nuclear Medicine, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Unit of Nuclear Medicine, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Calcagni","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Unit of Nuclear Medicine, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-2898","authenticated-orcid":false,"given":"Lucia","family":"Leccisotti","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Unit of Nuclear Medicine, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Moretti","sequence":"additional","affiliation":[{"name":"Unit\u00e0 della Fisica per le Scienze della Vita, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Ghai","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-236X","authenticated-orcid":false,"given":"Aleksandr","family":"Eismant","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2285-7783","authenticated-orcid":false,"given":"Tanay","family":"Parkar","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-8468","authenticated-orcid":false,"given":"Lukas","family":"Greifenstein","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-0075","authenticated-orcid":false,"given":"Richard Paul","family":"Baum","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: Structure, function, ligands, and new nomenclature","volume":"70","author":"Tulipano","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40658-017-0182-7","article-title":"Saul Hertz, MD, and the birth of radionuclide therapy","volume":"4","author":"Fahey","year":"2017","journal-title":"EJNMMI Phys."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1874471011104040306","article-title":"Actinium-225 in targeted alpha-particle therapeutic applications","volume":"4","author":"Scheinberg","year":"2011","journal-title":"Curr. Radiopharm."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pouget, J.P., and Constanzo, J. (2021). Revisiting the radiobiology of Targeted Alpha Therapy. Front. Med., 8.","DOI":"10.3389\/fmed.2021.692436"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.L., Chen, X., Baum, R.P., and Zhang, J. (2022). Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1034315"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","article-title":"Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: The mass effect","volume":"58","author":"Nicolas","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in patients with metastatic neuroendocrine neoplasms: Dosimetry, safety, and efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kanellopoulos, P., Nock, B.A., Greifenstein, L., Baum, R.P., Roesch, F., and Maina, T. (2022). 68Ga-DATA5m-LM4, a PET radiotracer in the diagnosis of SST2R-positive tumors: Preclinical and first clinical results. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314590"},{"key":"ref_15","unstructured":"Clinicaltrials.gov (2025, May 03). Phase 1b\/3 Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care Therapy in Subjects with Inoperable, Advanced, SSTR+, Well-Differentiated GEP-NETs that Have Progressed Following Prior 177Lu-SSA Therapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05477576."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"177Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_17","unstructured":"Clinicaltrials.gov (2025, May 03). A Phase III Multi-Center, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET with High Disease Burden (NETTER-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06784752."},{"key":"ref_18","unstructured":"National Institutes of Health, National Cancer Institute (2025, May 03). Common Terminology Criteria for Adverse Events (CTCAE) v 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: A single-institution series","volume":"46","author":"Goncalves","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","unstructured":"Clinicaltrials.gov (2025, May 03). A phase III Multi-Center, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03972488."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/RLU.0000000000005149","article-title":"Efficacy and safety of 225Ac-DOTATATE in the treatment of neuroendocrine neoplasms with high SSTR expression","volume":"49","author":"Yang","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2967\/jnumed.117.205161","article-title":"Somatostatin receptor imaging of neuroendocrine tumors: From agonists to antagonists","volume":"59","author":"Bodei","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41181-023-00197-0","article-title":"First preclinical evaluation of 225Ac-DOTA-JR11 and comparison with 177Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs","volume":"8","author":"Handula","year":"2023","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Perrone, E., Ghai, K., Eismant, A., Andreassen, M., Langer, S.W., Knigge, U., Kjaer, A., and Baum, R.P. (2024). Impressive response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu\/225Ac-DOTA-LM3 somatostatin receptor antagonist in a patient with therapy-refractory, rapidly progressive neuroendocrine neoplasm of the pancreas. Diagnostics, 14.","DOI":"10.3390\/diagnostics14090907"},{"key":"ref_30","first-page":"101","article-title":"First successful in-human application of 225Ac-DOTA-LM3 mono-PRRT for the treatment of an otherwise therapy-resistant Neuroendocrine Tumor (NET G3)","volume":"50","author":"Speicher","year":"2025","journal-title":"Clin. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2967\/jnumed.124.267611","article-title":"Is 161Tb really happening?","volume":"65","author":"Kong","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00259-024-06641-w","article-title":"First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist (161Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum","volume":"51","author":"Fricke","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2967\/jnumed.123.266774","article-title":"Is 212Pb really happening? The post-177Lu\/225Ac blockbuster?","volume":"65","author":"Zimmermann","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: First-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Winter, R.C., Amghar, M., Wacker, A.S., Bakos, G., Ta\u015f, H., Roscher, M., Kelly, J.M., and Bene\u0161ov\u00e1-Sch\u00e4fer, M. (2024). Future treatment strategies for cancer patients combining targeted alpha therapy with pillars of cancer treatment: External beam radiation therapy, checkpoint inhibition immunotherapy, cytostatic chemotherapy, and brachytherapy. Pharmaceuticals, 17.","DOI":"10.3390\/ph17081031"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7150\/thno.87345","article-title":"Improving susceptibility of neuroendocrine tumors to radionuclide therapies: Personalized approaches towards complementary treatments","volume":"14","author":"Richter","year":"2024","journal-title":"Theranostics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: A real-world scenario management based long-term outcome study","volume":"64","author":"Ballal","year":"2022","journal-title":"J. Nucl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:59Z","timestamp":1760035559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":38,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17183070"],"URL":"https:\/\/doi.org\/10.3390\/cancers17183070","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}